162 related articles for article (PubMed ID: 26592662)
41. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
42. Altered K
Seo CH; Cui HS; Kim JB
Transl Res; 2021 Oct; 236():133-146. PubMed ID: 33905948
[TBL] [Abstract][Full Text] [Related]
43. One-step synthesis of carbon-13-labeled globotriaosylsphingosine (lyso-Gb3), an internal standard for biomarker analysis of Fabry disease.
Hong X; Gelb MH
Mol Genet Metab; 2018 Nov; 125(3):292-294. PubMed ID: 30126819
[TBL] [Abstract][Full Text] [Related]
44. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
45. LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease.
Boutin M; Gagnon R; Lavoie P; Auray-Blais C
Clin Chim Acta; 2012 Dec; 414():273-80. PubMed ID: 23041216
[TBL] [Abstract][Full Text] [Related]
46. The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease.
Alharbi FJ; Baig S; Rambhatla SB; Vijapurapu R; Auray-Blais C; Boutin M; Steeds R; Wheeldon N; Dawson C; Geberhiwot T
Clin Chim Acta; 2020 Jan; 500():120-127. PubMed ID: 31654629
[TBL] [Abstract][Full Text] [Related]
47. The role of T cell potassium channels, KV1.3 and KCa3.1, in the inflammatory cascade in ulcerative colitis.
Hansen LK
Dan Med J; 2014 Nov; 61(11):B4946. PubMed ID: 25370966
[TBL] [Abstract][Full Text] [Related]
48. Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease.
Tsukimura T; Nakano S; Togawa T; Tanaka T; Saito S; Ohno K; Shibasaki F; Sakuraba H
Mol Genet Metab Rep; 2014; 1():288-298. PubMed ID: 27896103
[TBL] [Abstract][Full Text] [Related]
49. Oxidative stress promotes myocardial fibrosis by upregulating K
Wang LP; Fan SJ; Li SM; Wang XJ; Gao JL; Yang XH
Pflugers Arch; 2017 Sep; 469(9):1061-1071. PubMed ID: 28455747
[TBL] [Abstract][Full Text] [Related]
50. Lyso-globotriaosylsphingosine induces endothelial dysfunction
Hwang AR; Park S; Woo CH
Korean J Physiol Pharmacol; 2023 May; 27(3):231-240. PubMed ID: 37078297
[TBL] [Abstract][Full Text] [Related]
51. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
Auray-Blais C; Ntwari A; Clarke JT; Warnock DG; Oliveira JP; Young SP; Millington DS; Bichet DG; Sirrs S; West ML; Casey R; Hwu WL; Keutzer JM; Zhang XK; Gagnon R
Clin Chim Acta; 2010 Dec; 411(23-24):1906-14. PubMed ID: 20716442
[TBL] [Abstract][Full Text] [Related]
52. Incidental finding of cornea verticillata or lamellar inclusions in kidney biopsy: measurement of lyso-Gb3 in plasma defines between Fabry disease and drug-induced phospholipidosis.
Politei J; Frabasil J; Durand C; Di Pietrantonio S; Fernandez A; Albertón V; Velasquez Rivas D; Barriales-Villa R; Larrañaga-Moreira J; Schenone AB
Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165985. PubMed ID: 33022387
[TBL] [Abstract][Full Text] [Related]
53. Unraveling the drivers and consequences of gut microbiota disruption in Fabry disease: the lyso-Gb3 link.
Sanchez-Niño MD; Aguilera-Correa JJ; Politei J; Esteban J; Requena T; Ortiz A
Future Microbiol; 2020 Mar; 15():227-231. PubMed ID: 32271110
[No Abstract] [Full Text] [Related]
54. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics.
Auray-Blais C; Boutin M; Gagnon R; Dupont FO; Lavoie P; Clarke JT
Anal Chem; 2012 Mar; 84(6):2745-53. PubMed ID: 22309310
[TBL] [Abstract][Full Text] [Related]
55. A Short Synthetic Peptide Mimetic of Apolipoprotein A1 Mediates Cholesterol and Globotriaosylceramide Efflux from Fabry Fibroblasts.
Schueler U; Kaneski C; Remaley A; Demosky S; Dwyer N; Blanchette-Mackie J; Hanover J; Brady R
JIMD Rep; 2016; 29():69-75. PubMed ID: 26683465
[TBL] [Abstract][Full Text] [Related]
56. Downregulation of the Ca
Kito H; Morihiro H; Sakakibara Y; Endo K; Kajikuri J; Suzuki T; Ohya S
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C345-C358. PubMed ID: 32520608
[TBL] [Abstract][Full Text] [Related]
57. Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta.
Limgala RP; Jennelle T; Plassmeyer M; Boutin M; Lavoie P; Abaoui M; Auray-Blais C; Nedd K; Alpan O; Goker-Alpan O
Am J Transl Res; 2019; 11(3):1683-1696. PubMed ID: 30972193
[TBL] [Abstract][Full Text] [Related]
58. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.
Auray-Blais C; Lavoie P; Boutin M; Ntwari A; Hsu TR; Huang CK; Niu DM
Clin Chim Acta; 2017 Mar; 466():185-193. PubMed ID: 28108302
[TBL] [Abstract][Full Text] [Related]
59. Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy.
Thomaidis T; Relle M; Golbas M; Brochhausen C; Galle PR; Beck M; Schwarting A
Kidney Int; 2009 Feb; 75(4):399-407. PubMed ID: 19037253
[TBL] [Abstract][Full Text] [Related]
60. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.
Yasuda M; Huston MW; Pagant S; Gan L; St Martin S; Sproul S; Richards D; Ballaron S; Hettini K; Ledeboer A; Falese L; Cao L; Lu Y; Holmes MC; Meyer K; Desnick RJ; Wechsler T
Mol Ther Methods Clin Dev; 2020 Sep; 18():607-619. PubMed ID: 32775495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
